The company has received regulatory approvals from both CLIA and New York State and will offer the genomic microarray as part of its Kidney CompleteSM Program.
|According to the National Cancer Institute, it is estimated that 64,000 new kidney cancer cases will be diagnosed in the United States in 2013, while about 13,000 patients will die from the disease.|
Results from a research collaboration between Jonathan Coleman, MD, at Memorial Sloan-Kettering Cancer Center, and CGI based on the use of needle biopsy specimens were presented in a poster at the 2013 Genitourinary Cancers Symposium.
“The decision to treat a renal mass is based on the tumor’s biologic potential to metastasize to other sites in the body, where it can cause pain, debilitation, and death, but in many cases, these tumors may not be a threat and can be safely left alone under observation,” Coleman says. “The studies we have conducted demonstrate that it may be possible to better understand how a tumor will behave by analyzing the genetic makeup of tumor tissue obtained through biopsy.”
The UroGenRA™-Kidney has been developed to assist in the diagnosis of both needle biopsy and resected specimens. While in many cases, surgery is recommended after diagnosis, this test will help to devise proper therapy selection based on the tumor genomic profiling for kidney patients without the need for invasive surgery. This microarray test joins other proprietary genomic testing solutions offered by CGI that target personalized cancer treatment while reducing health care cost.
CGI’s reference lab is CLIA-certified and accredited by the CAP.
[Source: Cancer Genetics]